Concepedia

Karina Hermosillo Reséndiz

KH

Statistics

Publications

9

Citations

848

H-Index

9

Active since

2011

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Tris Pharma (United States)

University of Naples Federico II

University of Edinburgh

Karina Hermosillo Reséndiz is an author at Novartis (Switzerland) specializing in medicine, clinical pharmacology, and endocrinology.

Publications per year

2011–2017

9

Publications

9

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Annamaria Colao, Marcello D. Bronstein, Pamela U. Freda et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 394 citations · Full text

, , +17

Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study

Astrid Breitschaft, Ke Hu, Karina Hermosillo Reséndiz et al. · Diabetes Research and Clinical Practice · 2013 · 112 citations

, , +11

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Michael C. Sheppard, Marcello D. Bronstein, Pamela U. Freda et al. · Pituitary · 2014 · 81 citations · Full text

, , +11

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

Marcello D. Bronstein, Maria Fleseriu, Sebastian Neggers et al. · BMC Endocrine Disorders · 2016 · 78 citations · Full text

, , +10

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Stephan Petersenn, Andrew J. Farrall, Christophe De Block et al. · Pituitary · 2013 · 59 citations · Full text

, , +13

1–5 of 9